Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.

Zhang, Cuijian; Li, Yifan; Qian, Jinqin; Zhu, Zhenpeng; Huang, Cong; He, Zhisong; Zhou, Liqun; Gong, Yanqing

Zhang, Cuijian; Li, Yifan; Qian, Jinqin; Zhu, Zhenpeng; Huang, Cong; He, Zhisong; Zhou, Liqun; Gong, Yanqing.

Afiliação

Zhang C; Department of Urology, Peking University First Hospital, Beijing, China.
Li Y; Institute of Urology, Peking University, Beijing, China.
Qian J; National Urological Cancer Center, Peking University First Hospital, Beijing, China.
Zhu Z; Department of Urology, Peking University First Hospital, Beijing, China.
Huang C; Institute of Urology, Peking University, Beijing, China.
He Z; National Urological Cancer Center, Peking University First Hospital, Beijing, China.
Zhou L; Department of Urology, Peking University First Hospital, Beijing, China.
Gong Y; Institute of Urology, Peking University, Beijing, China.

Front Immunol ; 13: 1020729, 2022.

Article em En | MEDLINE | ID: mdl-36479115

Assuntos

Carcinoma de Células Renais; Carcinoma; Neoplasias Renais; Humanos; Carcinoma de Células Renais/genética; Carcinoma de Células Renais/terapia; Resultado do Tratamento; Microambiente Tumoral/genética; Claudinas/genética; Neoplasias Renais/genética; Neoplasias Renais/terapia

Palavras-chave

claudin; clear cell renal cell carcinoma (ccRCC); immune checkpoint inhibitor (ICI); immunity; prognosis; tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google